Opus Genetics, Inc. (NASDAQ: IRD) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | -1.27 | Insider Own | 22.77% | Shs Outstand | 82.57M | Perf Week | -14.24% |
| Market Cap | 427.69M | Forward P/E | - | EPS next Y | -0.70 | Insider Trans | -9.56% | Shs Float | 34.98M | Perf Month | 27.27% |
| Enterprise Value | 373.69M | PEG | - | EPS next Q | -0.14 | Inst Own | - | Short Float | 13.22% | Perf Quarter | 27.27% |
| Income | -108.00M | P/S | 42.77 | EPS this Y | 18.30% | Inst Trans | - | Short Ratio | 11.36 | Perf Half Y | 13.10% |
| Sales | 10.00M | P/B | - | EPS next Y | 32.31% | ROA | -115.75% | Short Interest | 10.91M | Perf YTD | 157.71% |
| Book/sh | -0.16 | P/C | 4.81 | EPS next 5Y | - | ROE | 1147.63% | 52W High | 7.07 -26.73% | Perf Year | 262.24% |
| Cash/sh | 1.08 | P/FCF | - | EPS past 3/5Y | - | ROIC | -59.29% | 52W Low | 1.41 267.38% | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | -29.53% - | Gross Margin | 99.87% | Volatility | 6.19% 10.04% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 37.37 | EPS Y/Y TTM | 40.93% | Oper. Margin | -513.47% | ATR (14) | 0.48 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 12.19 | Sales Y/Y TTM | -9.09% | Profit Margin | -1091.82% | RSI (14) | 58.14 | Recom | 2.00 |
| Dividend Gr. 3/5Y | - | Current Ratio | 12.19 | EPS Q/Q | -16.67% | SMA20 | 9.58% | Beta | 1.11 | Target Price | 12.60 |
| Payout | 0.00% | Debt/Eq | 0.00 | Sales Q/Q | -66.67% | SMA50 | 28.56% | Rel Volume | 2.43 | Prev Close | 5.28 |
| Employees | 28 | LT Debt/Eq | -2.69 | Earnings | Nov 11 | SMA200 | 34.33% | Avg Volume | 2.28M | Price | 5.18 |
| IPO Date | Jan 19, 2015 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 10.64% -71.27% | Net Debt/EBITDA | 0.51 | Volume | 5,540,976 | Change | -1.89% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Sep-09-26 | Reiterated | Oppenheimer | Outperform | $20 |
| Sep-09-26 | Reiterated | Chardan Capital | Buy | $16 |
| Aug-07-26 | Reiterated | RBC Capital | Outperform | $10 → $9.00 |
| Jun-23-26 | Initiated | RBC Capital | Outperform | $10 |
| Jun-17-26 | Reiterated | HC Wainwright & Co. | Buy | $8.00 |
| May-21-26 | Initiated | Leerink | Outperform | $10 |
| Mar-11-26 | Reiterated | Craig-Hallum | $9.00 | |
| Jan-20-26 | Initiated | BTIG | Buy | $7.00 |
| Nov-25-25 | Initiated | Piper Sandler | Overweight | $7.00 |
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refractive and retinal eye disorders. Its portfolio includes Phentolamine Ophthalmic Solution, currently used to reverse pharmacologically induced mydriasis (pupil dilation). This solution is also advancing through Phase III clinical trials for the treatment of presbyopia and impaired vision in dim light or at night. A leading candidate in its retinal pipeline is APX3330, a small-molecule inhibitor targeting the reduction oxidation effector factor-1 protein. APX3330 has successfully completed Phase II clinical trials for diabetic retinopathy. Furthermore, Opus Genetics is developing APX2009 and APX2014, two preclinical product candidates also aimed at various retinal indications. Originally founded in 2018 as Ocuphire Pharma, Inc., the company maintains its headquarters in Farmington Hills, Michigan.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 10 | 14 | 11 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 0 | 0 | 0 | — | — | — | — | — | |
| Gross Profit | 10 | 14 | 11 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 22 | 22 | 18 | — | — | — | — | — | |
| Research and Development | 38 | 31 | 27 | — | — | — | — | — | |
| Other Operating Expense | 0 | 0 | 28 | — | — | — | — | — | |
| Operating Income | -49 | -39 | -62 | — | — | — | — | — | |
| Interest Expense | 3 | 1 | 0 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -55 | -10 | 5 | — | — | — | — | — | |
| Net Income Before Taxes | -108 | -50 | -58 | — | — | — | — | — | |
| Income Taxes | 0 | 0 | 0 | — | — | — | — | — | |
| Consolidated Net Income | -108 | -50 | -58 | — | — | — | — | — | |
| Net Income From Continuing Operations | -108 | -50 | -58 | — | — | — | — | — | |
| Net Income | -108 | -50 | -58 | — | — | — | — | — | |
| EPS (Recurring) | -1.27 | -0.80 | -2.15 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -1.27 | -0.80 | -2.15 | — | — | — | — | — | |
| EPS (Diluted) | -1.27 | -0.80 | -2.15 | — | — | — | — | — | |
| EBITDA | -105 | -48 | -58 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 49.21 | 89.30 | 2.92 | — | — | — | — | — | |
| Gross Margin | 100.00 | 100.00 | 100.00 | — | — | — | — | — | |
| Operating Margin | -490.00 | -278.57 | -563.64 | — | — | — | — | — | |
| Net Margin | -1,080.00 | -357.14 | -527.27 | — | — | — | — | — | |
| Shares Outstanding | 95 | 622 | 27 | — | — | — | — | — | |
| Market Capitalization | 492 | 1,250 | 32 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Magrath George | Chief Executive Officer | Sep 09 '26 | Option Exercise | 1.15 | 392,157 | 450,981 | 2,124,026 | Sep 11 |
| Gallagher Cam | Director | Sep 08 '26 | Option Exercise | 1.15 | 784,314 | 901,961 | 2,800,111 | Sep 08 |
| Gagnon Robert E. | Chief Financial Officer | Sep 03 '26 | Sale | 4.54 | 28,000 | 127,212 | 556,375 | Sep 08 |
| YERXA BENJAMIN R | President | Jul 23 '26 | Sale | 2.97 | 7,429 | 22,064 | 704,106 | Jul 27 |
| SCHACHLE JOSEPH K | Chief Operating Officer | Jul 23 '26 | Sale | 2.94 | 4,644 | 13,653 | 291,440 | Jul 27 |
| Magrath George | Chief Executive Officer | Jul 23 '26 | Sale | 2.95 | 9,475 | 27,926 | 1,731,869 | Jul 27 |
| Gagnon Robert E. | Chief Financial Officer | Jul 23 '26 | Sale | 2.95 | 7,783 | 22,942 | 584,375 | Jul 27 |
| Foundation Fighting Blindness Retinal Degeneration Fund | director, other: See Remarks | May 18 '26 | Sale | 4.35 | 1,700,000 | 7,395,000 | 3,792,171 | May 20 |
| Zaremba Rabourn Amy | Head of Fin. Quality Assurance | Apr 23 '26 | Sale | 5.20 | 1,641 | 8,540 | 188,671 | Apr 27 |
| YERXA BENJAMIN R | President | Apr 23 '26 | Sale | 5.24 | 7,470 | 39,121 | 711,535 | Apr 27 |
| SCHACHLE JOSEPH K | Chief Operating Officer | Apr 23 '26 | Sale | 5.22 | 4,697 | 24,519 | 296,084 | Apr 27 |
| Magrath George | Chief Executive Officer | Apr 23 '26 | Sale | 5.22 | 9,511 | 49,647 | 1,741,344 | Apr 27 |
| Jayagopal Ashwath | Chief Scientific & Dev. Ofc. | Apr 23 '26 | Sale | 5.19 | 7,542 | 39,156 | 509,233 | Apr 27 |
| Gagnon Robert E. | Chief Financial Officer | Apr 23 '26 | Sale | 5.18 | 7,842 | 40,658 | 592,158 | Apr 27 |
| Magrath George | Chief Executive Officer | Mar 16 '26 | Sale | 5.21 | 24,438 | 127,327 | 1,750,855 | Mar 18 |